Preview

Systemic Hypertension

Advanced search

The treatment options of the new angiotensin II receptor blocker - azilsartan medoxomil in the therapy of hypertension in patients with metabolic disorders

Abstract

One of the key pathogenic mechanisms of the arterial hypertension (AH) development in patients with metabolic syndrome is the activation of the renin-angiotensin-aldosterone system (RAAS). According to these advantages we need to use drugs inhibiting the RAAS in the treatment of AH patients. This article demonstrates the information about the new Angiotensin II receptor blocker (azilsartan) application in AH patients with metabolic disorders. There are several studies showing the high antihypertensive efficiency of azilsartan as compared with other antihypertensive drug classes in patients with obesity and metabolic disorders. According to the pilot studies, azilsartan has additional positive metabolic effects: increases tissue sensitivity to insulin and reduces body fat mass.

About the Authors

Yu. V. Zhernakov
ИКК им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, Москва
Russian Federation


I. Ye. Chazova
ИКК им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, Москва
Russian Federation


References

1. Jordan J, Yumuk V, Schalaich M et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30 (6): 1047-55.

2. Kotseva K, Wood D, de Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16 (2): 121-37.

3. International Diabetes Federation. Diabetes Atlas Update 5-th ed, 2012; www.idf.org/diabetesatlas

4. Haffner S.M et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.

5. Ryden L, Grant P.G, Anker S.D et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre - diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J; doi:10.1093/eurheartj/eht108

6. Olivares-Reyes J.A, Arellano-Plancarte A, Castillo-Hernandez J.R. Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302: 128-39.

7. Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Дис. ... д - ра мед. наук. М., 2012.

8. Шарипова Г.М. Особенности поражения органов - мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Дис. ... д - ра мед. наук. М., 2009.

9. Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201-7.

10. Straessen J.A, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282 (6): 539-46.

11. Edarbi R (azilsartan medoxomil) prescribing information, Takeda Pharmaceuticals USA, Inc 2012. Takeda Pharmaceutical Company Limited.

12. Bonner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.

13. White W.B et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.

14. Rakugi H et al. Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension. Hypertens Res 2012; 35: 552-8.

15. Kusumoto K et al. Antihypertensive, insulin - sensitising and renoprotective effects of a novel, potent and long - acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011; 669: 84-93.

16. Iwai M et al. TAK-536, a new АТ1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-86.


Review

For citations:


Zhernakov Yu.V., Chazova I.Ye. The treatment options of the new angiotensin II receptor blocker - azilsartan medoxomil in the therapy of hypertension in patients with metabolic disorders. Systemic Hypertension. 2014;11(4):58-61.

Views: 131


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2075-082X (Print)
ISSN 2542-2189 (Online)